Background . The efficacy and tolerability of peginterferon α -2a and peginterferon α -2b in chronic hepatitis C (CHC) patients remain controversial. Methods . PubMed, Ovid, and Cochrane libraries were electronically searched until August 30, 2012. Studies that met the inclusion criteria were systematically evaluated by two reviewers independently. Results . The overall sustained virologic response (SVR) rate of the peginterferon α -2a group was significantly higher than that of the peginterferon α -2b group (46.7% versus 42.4%, P value = 0.01). The same tendency was observed for naïve, genotype 1/4, and genotype 2/3 patients. The early virologic response (EVR) and end-of-treatment response (ETR) rates were significantly higher in the peginterferon α -2a group than in the peginterferon α -2b group (56.1% versus 49.8%, P<0.0001 ; 67.9% versus 56.6%, P<0.00001 , resp.). Peginterferon α -2a had a significantly lower discontinuation rate than peginterferon α -2b (27.9% versus 33.9%, P<0.0001 ) in naïve patients. In both naïve CHC and hepatitis C virus genotype 1 patients, peginterferon α -2a had a higher relapse rate than peginterferon α -2b. Conclusions . Peginterferon α -2a has superior efficacy with higher EVR, ETR, and SVR than peginterferon α -2b for CHC patients, both plus ribavirin. Peginterferon α -2a might obtain a similar or even lower discontinuation rate than peginterferon α -2b. However, peginterferon α -2a had a higher relapse rate than peginterferon α -2b.
Yang, Z., Zhuang, L., Yang, L., & Chen, X. (2013). Efficacy and Tolerability of Peginterferon α -2a and Peginterferon α -2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials . Gastroenterology Research and Practice, 2013, 1–11. https://doi.org/10.1155/2013/739029